(19)
(11) EP 2 490 632 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.03.2017 Bulletin 2017/11

(45) Mention of the grant of the patent:
26.10.2016 Bulletin 2016/43

(21) Application number: 10757691.0

(22) Date of filing: 16.09.2010
(51) International Patent Classification (IPC): 
A61F 6/22(2006.01)
(86) International application number:
PCT/US2010/049188
(87) International publication number:
WO 2011/049694 (28.04.2011 Gazette 2011/17)

(54)

CONTRACEPTIVE DEVICES

VERHÜTUNGSVORRICHTUNGEN

DISPOSITIFS DE CONTRACEPTION

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 23.10.2009 US 605304

(43) Date of publication of application:
29.08.2012 Bulletin 2012/35

(73) Proprietor: Bayer Essure Inc.
Whippany, NJ 07981 (US)

(72) Inventors:
  • GOPAL, Vidya
    Fremont, CA 94538 (US)
  • STOUT, Christopher
    San Bruno, CA 94066 (US)
  • SWANN, Betsy
    Grass Valley, CA 95945 (US)

(74) Representative: BIP Patents 
c/o Bayer Intellectual Property GmbH Alfred-Nobel-Straße 10
40789 Monheim am Rhein
40789 Monheim am Rhein (DE)


(56) References cited: : 
WO-A1-2006/102329
US-A1- 2005 274 384
 US-A1- 2004 059 370
US-A1- 2007 056 591
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).